Compare Tango Therapeutics Inc. (TNGX) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vital Farms Inc — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Vital Farms Inc trades at $8.83 (market cap $400.98M). The key difference: Tango Therapeutics Inc. is far larger — about 9.4× Vital Farms Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vital Farms Inc for 15 Days on average.
| TNGX | VITL | |
|---|---|---|
Market Cap | $3.75B | $400.98M |
Volume | 9,619,106 | 1,181,598 |
Sector | Health | Consumer Staples |
52-Week High | $32.90 | $40.85 |
52-Week Low | $7.50 | $8.28 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $2.77B | $487.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Vital Farms (VITL) trades at $9.34, down 1.37% amid bearish technical signals and challenging fundamentals. The stock faces pressure from declining earnings, with Q1 2026 missing expectations and Q3 2026 expected at -$0.13 EPS. Despite a 56% analyst buy rating and $13.11 consensus target, recent news highlights strategic review discussions and pricing pressures in the egg market. Revenue remains flat at $766M for 2026 with net margins collapsing to near-zero, while cash flow trends show significant operational challenges.
The outlook remains cautious with near-term headwinds from industry oversupply and margin compression. Investment opportunity exists if strategic options materialize, but risks include sustained profitability challenges and competitive pressures. Current valuation metrics suggest potential upside if execution improves, but investors should monitor Q3 earnings and strategic developments closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
